TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9844330
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg at bedtime as maintenance therapy for one year
Study: 405433
Drug: APPG (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: APPG (4.8 X 10(6) units of aqueous procaine penicillin G intramuscularly plus 1 g of probenecid orally)
Study: 405433
Drug: TMP‐SMZ‐9 (nine
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP‐SMZ‐9 (nine tablets of trimethoprim‐sulfamethoxazole; 720 mg of TMP and 3,600 mg of SMZ, orally as a single dose)
Study: 405433
Drug: TMP‐SMZ‐12 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP‐SMZ‐12 (12 tablets of TMP‐SMZ; 960 mg of TMP and 4,800 mg of SMZ, orally as two doses of six tablets taken at a 6‐hr interval)
Study: 405433
Drug: Neisseria gonorrhoeae
Normalized name: Neisseria gonorrhoeae Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neisseria gonorrhoeae treatment failures
Study: 27402427
Drug: Short (6-mm)
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short (6-mm) dental implants (TG)
Study: 27402427
Drug: Sinus floor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinus floor elevation (SFE) with longer (≥10-mm) implants (CG)
Study: 25865751
Drug: 10 mg/ml
Normalized name: urea 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/ml of pectin
Study: 25865751
Drug: 0, 3
Normalized name: Co-Q10, 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0, 3 and 10 mg/ml of pectin
Study: 19621660
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 g intravenously after induction of anesthesia
Study: 16724543
Drug: Bronchobos capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchobos capsules (750 mg)
Study: 16724543
Drug: Mucopront capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucopront capsules (750 mg)
Study: 9257324
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine (60 mg administered six times/d)
Study: 7687093
Drug: Midodrine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (any dose)
Study: 3829296
Drug: Oral ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ranitidine 150 mg with 150 ml water
Study: 3829296
Drug: Oral ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ranitidine 150 mg with no further fluid
Study: 3829296
Drug: Oral ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ranitidine 150 mg (both groups)
Study: 31126694
Drug: Contezolid 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contezolid 1200 mg
Study: 31126694
Drug: Contezolid 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contezolid 1600 mg
Study: 31126694
Drug: Contezolid 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contezolid 800 mg
Study: 21779740
Drug: Electroacupuncture pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture pulse stimulation therapy alone
Study: 21779740
Drug: Massage combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage combined with electroacupuncture pulse stimulation therapy
Study: 24526184
Drug: Pramipexole (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (0.5 mg)
Study: 19220275
Drug: L-dopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (100 mg)
Study: 9597557
Drug: Eprosartan 400
Normalized name: eprosartan 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 400 mg
Study: 9597557
Drug: Eprosartan 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 800 mg
Study: 2893037
Drug: Non-invasive strategy
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive strategy with thrombolysis (rTPA), heparin, and acetylsalicylic acid without immediate angiography and PTCA
Study: 31169023
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab treatment for choroidal neovascularization due to pathologic myopia
Study: 24077657
Drug: Intensive psychotherapy
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive psychotherapy (family‐focused therapy, interpersonal and social rhythm therapy, or cognitive‐behavioral therapy)
Study: 24077657
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care (three‐session comparison treatment)
Study: 24032193
Drug: Behavior training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior training after acupuncture treatment
Study: 20452733
Drug: Transdermal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal steroid delivery via iontophoresis or phonophoresis
Study: 20452733
Drug: Transdermal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal steroid delivery via iontophoresis
Study: 20452733
Drug: Transdermal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal steroid delivery via phonophoresis
Study: 7972572
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 35% CO2/65% O2 gas mixture
Study: 7972572
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of air (placebo condition)
Study: 4907811
Drug: Propranolol (120-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120-320 mg daily)
Study: 29797990
Drug: Anti-anxiety and
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-anxiety and anti-depression treatment (experimental group)
Study: 29797990
Drug: No anti-anxiety
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-anxiety and anti-depression treatment (control group)
Study: 29797990
Drug: Anti-anxiety and
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-anxiety and anti-depression treatment (experimental group) for tinnitus
Study: 29797990
Drug: No anti-anxiety
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-anxiety and anti-depression treatment (control group) for tinnitus
Study: 17303710
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (3-g intravenous infusion)
Study: 9892907
Drug: Interferon-gamma treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-gamma treatment
Study: 2697199
Drug: mazindol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: mazindol (2 mg/d)
Study: 4584640
Drug: Deglycyrrhizinated liquorice
Normalized name: Liquorice
DrugBank: Licorice (DB10675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deglycyrrhizinated liquorice extract (760 mg three times daily)
Study: 26443438
Drug: R25 Reciproc
Approvals — FDA: no, EMA: no, PMDA: no
Description: R25 Reciproc preparation
Study: 26443438
Drug: Conventional hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hand filing preparation
Study: 10429571
Drug: Interauricular low‐intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interauricular low‐intensity infrared laser therapy (0.89 nm, 7.6 J/cm)
Study: 10429571
Drug: Interauricular laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interauricular laser therapy
Study: 8850249
Drug: UVB irradiation
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UVB irradiation (4 times the minimal erythema dose)
Study: 2163421
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg once a day
Study: 25981908
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy delivered through a face mask
Study: 24180712
Drug: Levosimendan (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (12 µg/kg bolus over 15 minutes, followed by 0.2 µg/kg/min infusion for 24 hours)
Study: 24180712
Drug: Dobutamine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (7.5 µg/kg/min infusion for 24 hours)
Study: 10775816
Drug: Pre‐emptive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐emptive therapy with ganciclovir
Study: 9185458
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard lidocaine infusion)
Study: 3948546
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen therapy to raise PaO2 ≥ 60 mm Hg (group 1, n = 6)
Study: 3948546
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen therapy to raise PvO2 ≥ 36 mm Hg (group 2, n = 6)
Study: 28295425
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of atropine administered before deflation of the cryoballoon (trial group)
Study: 28295425
Drug: Atropine administered
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine administered after the onset of hemodynamic variation (control group)
Study: 28295425
Drug: Prophylactic atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic atropine administration
Study: 25201758
Drug: Active group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group (patients chose route of administration)
Study: 25201758
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (physician decided route of administration)
Study: 25201758
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sublingual immunotherapy)
Study: 8067760
Drug: LY217896 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY217896 (75 mg) once daily for 7 days
Study: 28320223
Drug: Valbenazine 40
Normalized name: valbenazine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valbenazine 40 mg/day
Study: 28320223
Drug: Valbenazine 80
Normalized name: valbenazine 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valbenazine 80 mg/day
Study: 19847073
Drug: Memory training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memory training (e.g. memory skills training, imagery, method of loci)
Study: 9890849
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide gas at graded concentrations (n = 8)
Study: 9890849
Drug: Intravenous isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isosorbide dinitrate, 2.5 mg (n = 8)
Study: 28301690
Drug: ATG-10 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG-10 (10 mg/kg)
Study: 28301690
Drug: ATG-6 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG-6 (6 mg/kg)
Study: 18663579
Drug: Hypodermic needle
Normalized name: Hypodermic Needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypodermic needle (25‐G)
Study: 16551310
Drug: Increased fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased fluid intake by 1.5 L of water
Study: 16551310
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication (8 mL inactive syrup per day)
Study: 15621108
Drug: Triple dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple dosing of basiliximab (3 doses: prior to transplantation, day 4, and day 21)
Study: 15621108
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of basiliximab (prior to transplantation and day 4)
Study: 10752804
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) 25 mg and glucose 5 g administered simultaneously
Study: 8883420
Drug: STn linked
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STn linked to KLH with DETOX-B adjuvant, 100 micrograms, subcutaneous injection at weeks 0, 2, 5, and 9, with low-dose cyclophosphamide (CTX, 300 mg m-2) pretreatment.
Study: 8883420
Drug: STn linked
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STn linked to KLH with DETOX-B adjuvant, 100 micrograms, subcutaneous injection at weeks 0, 2, 5, and 9, without low-dose cyclophosphamide (CTX, 300 mg m-2) pretreatment.
Study: 6374537
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.625 mg per day
Study: 6374537
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 1.25 mg per day
Study: 6374537
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens <0.625 mg per day
Study: 29471904
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (IPT) for 6 months with pyridoxine
Study: 19128642
Drug: Betahistine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (24 mg/d for 1 month)
Study: 19128642
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between exercise and medication groups
Study: 15871016
Drug: (131)I plus
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: (131)I plus lithium (group I+L)
Study: 12836801
Drug: Educational Treatment
Normalized name: OneTouch Ultra Mini Educational Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational Treatment (ET)
Study: 8881455
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with low serum TSH (< 0.4 mU/l) (n = 44)
Study: 8881455
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with TSH > 4.0 mU/l (n = 44)
Study: 1810019
Drug: Naproxen 1000
Normalized name: naproxen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 1000 mg daily for 4 days
Study: 17825130
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg/day for Week 1 followed by 20 mg/day thereafter)
Study: 15741841
Drug: 1.2 g.min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g.min of maltodextrin + 0.6 g.min of fructose (MD+F)
Study: 15741841
Drug: 1.8 g.min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g.min of maltodextrin (MD)
Study: 11316178
Drug: Antibiotics (norfloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (norfloxacin and neomycin)
Study: 9390597
Drug: Thiopental 4
Normalized name: thiopental 400 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 4 mg/kg
Study: 9141939
Drug: Ketamine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1.5 mg/kg
Study: 30729953
Drug: Terlipressin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin infusion at 3 μg/kg/h, halved after arterial anastomosis and continued for 3 days
Study: 30729953
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no terlipressin infusion)
Study: 23471131
Drug: 900‐mg phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900‐mg phosphate diet plus lanthanum carbonate (LC)
Study: 23471131
Drug: 900‐mg phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900‐mg phosphate diet
Study: 21455083
Drug: Haptic rendering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haptic rendering of bone surface, skin pop, dura pop, and subcutaneous tissue.
Study: 15028362
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT) switched on
Study: 9093988
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g CPP
Study: 9093988
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g CPP
Study: 9093988
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g CPP
Study: 9093988
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g CPP (whole-grain cereal)
Study: 9093988
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g CPP (whole-grain cereal)
Study: 9093988
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g CPP (whole-grain cereal)
Study: 2834938
Drug: Enalaprilat (intravenous)
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalaprilat (intravenous)
Study: 29381802
Drug: Glucose-containing beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-containing beverage (75 g glucose dissolved in 300 mL water) at 22°C
Study: 29381802
Drug: Glucose-containing beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-containing beverage (75 g glucose dissolved in 300 mL water) at 0°C
Study: 26065720
Drug: CPAP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP plus conservative care (CC) for 3 months
Study: 19902277
Drug: Conservative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative care (CC)
Study: 19195513
Drug: ABT-335 +
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-335 + atorvastatin 20 mg
Study: 19195513
Drug: ABT-335 +
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-335 + atorvastatin 40 mg
Study: 11349176
Drug: Ampicillin and
Normalized name: Ampicillin and sulbactam only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin and Penicillin G
Study: 326052
Drug: Acetazolamide (Diamox)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (Diamox) administered to 24 eyes
Study: 25403306
Drug: Mexidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol (1 tablet (125 mg) 3 times a day for 3 weeks) along with standard treatment
Study: 20813517
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 1.25mg and sufentanil 5 μg with morphine 50 μg
Study: 20813517
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 1.25mg and sufentanil 5 μg with morphine 100 μg
Study: 20813517
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 1.25mg and sufentanil 5 μg with saline placebo
Study: 15833887
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 125 microg twice daily for 3 weeks and once daily for a fourth week (dosage doubled for infants > or =1200 g)
Study: 11981357
Drug: 2 NRTIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 NRTIs + 1 protease inhibitor (stavudine + lamivudine + indinavir)
Study: 11981357
Drug: 2 NRTIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 NRTIs + 1 nonnucleoside reverse transcriptase inhibitor (stavudine + didanosine + nevirapine)
Study: 8918498
Drug: Weight-based doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based doses of CAF regimen (cyclophosphamide, doxorubicin, and fluorouracil)
Study: 6760379
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg trimipramine at bedtime for 4 weeks
Study: 28371461
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine + insulin glargine 300 U/mL (G + G300)
Study: 28371461
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro + insulin glargine biosimilar (L + GB)
Study: 11472279
Drug: Music in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music in combination with therapeutic suggestions
Study: 9720727
Drug: Zidovudine and
Normalized name: zidovudine and lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine and alpha-interferon (proposed treatment)
Study: 2805034
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 120 mg daily
Study: 961472
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) administered as a single oral dose with food
Study: 961472
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) administered as a single oral dose in fasting state
Study: 26018048
Drug: MISSION‐Vet Implementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MISSION‐Vet Implementation as Usual (IU) - standard training and access to the MISSION‐Vet treatment manuals
Study: 11185998
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) at 1 to 2 g/kg
Study: 11185998
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral prednisolone (o‐PSL) (2 mg/kg for 2 weeks)
Study: 11185998
Drug: Parenteral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral methylprednisolone (mPSL) (5 mg/kg for 5 days)
Study: 11185998
Drug: Pulsed parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed parenteral methylprednisolone (PmPSL) (30 mg/kg for 3 days)
Study: 8349375
Drug: gallopamil, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallopamil, 150 mg/day
Study: 8349375
Drug: nifedipine, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine, 30 mg/day
Study: 3304725
Drug: Danazol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (50 to 600 mg daily for 6 months)
Study: 24878174
Drug: Topical ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular hypotensive medications
Study: 20175241
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 mu g/kg iv administered over 5 min)
Study: 17272962
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d quinapril plus 5 mg/d amlodipine besylate
Study: 17272962
Drug: 40 mg/d
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/d quinapril
Study: 7843751
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg losartan and 20 mg enalapril